您当前所在的位置:首页 > 产品中心 > 产品信息
CPNQ_分子结构_CAS_115687-05-3)
点击图片或这里关闭

CPNQ

产品号 C3118 公司名称 Sigma Aldrich
CAS号 115687-05-3 公司网站 http://www.sigmaaldrich.com
分子式 C20H17ClN4O3 电 话 1-800-521-8956
分子量 396.82698 传 真
纯 度 ≥98% (HPLC) 电子邮件
保 存 Chembase数据库ID: 153967

产品价格信息

请登录

产品别名

标题
CPNQ
IUPAC标准名
5-[4-(4-chlorobenzoyl)piperazin-1-yl]-8-nitroquinoline
IUPAC传统名
5-[4-(4-chlorobenzoyl)piperazin-1-yl]-8-nitroquinoline
别名
5-[4-(4-chlorobenzoyl)-1-piperazinyl]-8-nitroquinoline
B2

产品登记号

CAS号 115687-05-3
MDL号 MFCD02039810

产品性质

GHS警示性声明 P261-P301 + P310-P305 + P351 + P338
RID/ADR UN 2811 6.1/PG 3
危险公开号 25-36/37/38
安全公开号 26-45
保存温度 2-8°C
联合国危险货物等级 6.1
联合国危险货物编号 2811
联合国危险货物包装类别(PG) 3
德国WGK号 3
GHS危险品标识 GHS06
GHS警示词 Danger
GHS危险声明 H301-H315-H319-H335
欧盟危险性物质标志 有毒(Toxic) 有毒(Toxic) (T)
MSDS下载 下载链接
个人保护装置 Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
Empirical Formula (Hill Notation) C20H17ClN4O3
纯度 ≥98% (HPLC)
外观 brown solid
溶解度 H2O: insoluble <2 mg/mL
溶解度 DMSO: >5 mg/mL

产品详细信息

详细说明 (English)
Other Notes
Product is air sensitive.
Biochem/physiol Actions
Misfolded proteins accumulate in many neurodegenerative diseases, including huntingtin in Huntington′s disease and alpha-synuclein in Parkinson′s disease. The disease-causing proteins can take various conformations and are prone to aggregate and form larger cytoplasmic or nuclear inclusions. CPNQ (B2) was identified as a compound that promotes inclusion formation in cellular models of both Huntington′s disease and Parkinson′s disease. Despite the aggregate-forming specifics the compound prevents huntingtin-mediated proteasome dysfunction and reduces alpha-synuclein-mediated toxicity. These results demonstrate that compounds that increase inclusion formation may actually lessen cellular pathology in both Huntington′s and Parkinson′s diseases, suggesting a therapeutic approach for neurodegenerative diseases caused by protein misfolding. The ability of B2 to prevent toxicity, despite increasing inclusions, suggests that inclusions are beneficial rather than toxic, which will be further explored as the molecular target and mechanism. CPNQ (B2) is a desirable tool for both Huntington′s and Parkinson′s research.
详细说明 (简体中文)
Other Notes
Product is air sensitive.
Biochem/physiol Actions
Misfolded proteins accumulate in many neurodegenerative diseases, including huntingtin in Huntington′s disease and alpha-synuclein in Parkinson′s disease. The disease-causing proteins can take various conformations and are prone to aggregate and form larger cytoplasmic or nuclear inclusions. CPNQ (B2) was identified as a compound that promotes inclusion formation in cellular models of both Huntington′s disease and Parkinson′s disease. Despite the aggregate-forming specifics the compound prevents huntingtin-mediated proteasome dysfunction and reduces alpha-synuclein-mediated toxicity. These results demonstrate that compounds that increase inclusion formation may actually lessen cellular pathology in both Huntington′s and Parkinson′s diseases, suggesting a therapeutic approach for neurodegenerative diseases caused by protein misfolding. The ability of B2 to prevent toxicity, despite increasing inclusions, suggests that inclusions are beneficial rather than toxic, which will be further explored as the molecular target and mechanism. CPNQ (B2) is a desirable tool for both Huntington′s and Parkinson′s research.

参考文献